TABLE 3

Retinopathy outcomes during the first 4 and 10 years of EDIC follow-up among adults free of that outcome at DCCT closeout who had retinopathy evaluated at EDIC year 10

Retinopathy outcome*DCCT closeoutEDIC year 4§EDIC year 10§
INTCONOdds reduction (95% CI)PINTCONOdds reduction (95% CI)PINTCONOdds reduction (95% CI)P
≥Three-step progression from DCCT baseline (%)8.630.879 (70–85)<0.000111.426.764 (47–76)<0.000129.344.348 (31–61)<0.0001
    n523532431330475368
SNPDR+ (%)2.17.071 (43–86)0.00022.210.281 (62–90)<0.00016.319.673 (58–82)<0.0001
    n523532464449512495
PDR+ (%)2.16.871 (41–85)0.00021.79.383 (63–92)<0.00016.119.674 (59–83)<0.0001
    n523532464450512496
CSME (%)3.78.459 (28–76)0.00140.47.594 (77–99)<0.00015.214.166 (46–79)<0.0001
    n516510450429497468
Photocoagulation therapy (focal or scatter) (%)3.18.566 (38–81)0.00021.06.485 (61–94)<0.00014.916.874 (59–84)<0.0001
    n523532507487507487
  • *Patients with scatter photocoagulation after entry into the DCCT were counted as worse for retinopathy; those with focal photocoagulation were counted as worse for macular edema.

  • †INT is the former DCCT intensive group and CON is the former DCCT conventional group.

  • ‡The odds reduction is for intensive therapy compared with conventional therapy.

  • §n at EDIC years 4 and 10 is limited to those free of particular events at DCCT closeout. Data in boldface are statistically significant.